Additional investment in Encoded Therapeutics
RTW Biotech Opportunities Ltd
11 September 2026
LEI: 549300Q7EXQQH6KF7Z84
11 September 2026
RTW Biotech Opportunities Ltd
Additional investment in Encoded Therapeutics
· $275 million financing to advance ETX101 through pivotal development in Dravet syndrome
· RTW Bio invested $4.1 million as part of the Series F
· As at 31 July 2026, Encoded represented 0.1% of the Company's NAV
RTW Biotech Opportunities Ltd ("the Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note an additional investment in the $275 million Series F financing of private portfolio company Encoded Therapeutics ("Encoded").
Encoded is a clinical-stage biotechnology company developing one-time precision genetic medicines for severe neurological disorders. Encoded's lead programme, ETX101, is a one-time gene therapy for patients with Dravet syndrome, a severe, treatment-resistant childhood epilepsy for which no approved therapy addresses the underlying genetic cause. Proceeds from the Series F are expected to fund pivotal and expansion studies of ETX101 in Dravet syndrome, commercial scale-up of Encoded's manufacturing facility, and continued advancement of its broader neurology pipeline.
RTW Bio first invested in Encoded's Series D in June 2020 and has invested a further $4.1 million as part of this financing. As at 31 July 2026, Encoded represented 0.1% of the Company's NAV.
Rod Wong, CIO of RTW Investments, said, "Dravet syndrome is a devastating epilepsy for which no approved treatment targets the underlying cause. Encoded has delivered encouraging Phase 1/2 data, secured RMAT designation from the FDA and prepared ETX101 to enter pivotal development. This is one of the largest private financings of a CNS gene therapy company in recent years and is a strong endorsement of Encoded's science. It also underscores the potential for further value realisation in RTW Bio's portfolio as key programmes mature toward the clinic and public markets."
The announcement can be found here.
Enquiries:
|
RTW Investments, LP - Investment Manager Oliver Kenyon Krisha McCune (Investor Relations) |
+44 (0)20 7959 6362 biotechopportunities@rtwfunds.com |
|
Cadarn Capital - PR & IR Partner Lucy Clark (PR) David Harris (Distribution) |
+44 (0)7984 184 461 / lucy@cadarncapital.com +44 (0)7368 883 211 / david@cadarncapital.com |
|
Jefferies International Limited - Joint Corporate Broker Gaudi Le Roux Harry Randall-Knowles |
+44 (0)20 7029 8000 |
|
BofA Securities - Joint Corporate Broker Edward Peel Alex Penney |
+44 (0)20 7628 1000 |
|
Altum (Guernsey) Limited Joanna Duquemin Nicolle Sadie Morrison |
+44 (0)1481 703 100 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwbio.com for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.